Faron Information

View Top Employees from Faron

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

Website	https://www.faron.com
Ticker	FARN
Revenue	$6.5 million
Funding	$33.6 million
Employees	59 (27 on RocketReach)
Founded	2007
Address	6 Joukahaisenkatu, Turku, Southwest Finland FI-20520, FI
Fax	+358 2 4695152
Technologies	JavaScript , HTML , PHP +16 more (view full list)
Industry	Pharmaceuticals, Pharmaceutical Manufacturing, Drug discovery, Healthcare, Drug development, Novel treatments for medical conditions with significant unmet n, ARDS, Acute Respiratory Distress Syndrome, Cancer immunotherapy
Keywords	Biopharmaceutical, Clinical Stage, Novel Treatments, Immunotherapy, Drug Development, Unmet Medical Needs, Pharmaceutical Research, Biotechnology, Therapeutics, Medicine, Healthcare, Clinical Trials, Medical Research, Drug Discovery, Life Sciences, Biologics
Competitors	Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Amgen +44 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 873 Companies, SIC Code 87 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies